77.83 +0.17 (0.22%)
Pre-Market: 5:00AM EDT
|Bid||76.93 x 1800|
|Ask||78.83 x 900|
|Day's Range||76.53 - 77.72|
|52 Week Range||74.13 - 147.17|
|PE Ratio (TTM)||21.34|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||113.96|
Wall Street was split Wednesday on Celgene as one sell-side analyst downgraded the stock saying it "has tilted to greater risk" while another upgraded shares.
NEW YORK, May 23, 2018-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors ...
It's been two years since David's picked a batch of stocks made to thrive in a global society that's ever more focused on the life of the mind.
Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102. By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.
Celgene Corp. sell-side analysts can’t agree on what’s next for the company with shares hovering near a four-year low. Argus analyst David Toung moved to the sidelines on a risk-reward that has “tilted to greater risk” given an over-reliance on one of the world’s biggest brand-name cancer treatments, Revlimid. Shares tumbled on Monday to a four-year low after a news article about the departure of its former business development head, George Golumbeski, added gasoline to the fire of concerns for the drugmaker.
The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.
Law Offices of Howard G. Smith reminds investors of the May 29, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Celgene Corporation (“Celgene” or the “Company”) (NASDAQ: CELG) securities between January 12, 2015 and February 27, 2018, inclusive (the “Class Period”). Celgene investors have until May 29, 2018 to file a lead plaintiff motion.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Celgene Corporation (“Celgene” or the “Company”) (CELG) of the May 29, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Celgene stock or options between September 12, 2016 and February 27, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/CELG. There is no cost or obligation to you.
Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.
After years of growth, Celgene Corporation (NASDAQ:CELG) has spent the past eight months suffering from ever-weakening price action. In fact and with shares of Celgene now off a full 50% from 2017’s all-time-highs following Monday’s 4.70% price drop, you could say bears have been acting with barely any hesitation in CELG stock. The latest ‘disappointment’ in shares of Celgene, judging by Monday’s price reaction, is a report that Celgene’s top dog of business development discreetly retired over a month ago.
NEW YORK, May 22, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Celgene Corporation between January ...
Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...
NEW YORK, NY / ACCESSWIRE / May 22, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Celgene Corporation (''Celgene'' or the ''Company'') (CELG) and certain of its officers, on behalf of shareholders who purchased Celgene securities between January 12, 2015 and February 27, 2018, inclusive (the ''Class Period''). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
First we gauge the performance of David’s recommendations. Then, he interviews Middleby Corp.'s remarkable leader, Selim Bassoul.
NEW YORK, NY / ACCESSWIRE / May 22, 2018 / U.S. equities closed up on Monday, with the Dow Jones bouncing back to 25,000 milestones. Tension between U.S. and China eased after statement from Treasury Secretary ...
SCYNEXIS (SCYX) witnessed a 28% rise in its stock price in the week ended May 18. On May 18, SCYNEXIS stock closed at $1.63, which is ~14.4% growth from its previous close of $1.43 on May 17. SCYNEXIS stock rose ~27% over the last month. SCYNEXIS is a biotechnology company focused on the development of innovative therapies for the treatment of patients with difficult-to-treat and life-threatening infections.
The S&P 500’s top losses on May 21 were: Fifth Third Bancorp (FITB) declined 7.9%. Celgene (CELG) declined 4.7%. Symantec (SYMC) declined 2.7%. Allergan (AGN) declined 2.7%. Campbell Soup (CPB) declined 2.3%. Fifth Third Bancorp
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Celgene Corporation (CELG) (“Celgene” or the “Company”) securities during the period between September 12, 2016 and February 27, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 29, 2018 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Celgene securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.
U.S. biotechnology company Celgene Corp. ( CELG) has entered into a long-term strategic drug discovery and development partnership with Hamburg, Germany-based Evotec AG. In a brief statement, Evotec said it will receive an upfront payment of $65 million for its role in the partnership, as well as the potential to earn “significant milestone payments” and “tiered royalties” on each licensed program. Celgene and Evotec have already partnered up before.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the May 29, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Celgene Corporation (“Celgene” or the “Company”) (NASDAQ: CELG) securities between January 12, 2015 and February 27, 2018, inclusive (the “Class Period”). To obtain information or actively participate in the class action, please visit the Celgene page on our website at www.glancylaw.com/case/celgene-corporation. Investors suffering losses on their Celgene investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to firstname.lastname@example.org.
Celgene plunged to another four-year low Monday on a report that an executive in charge of business development quietly retired in mid-April.
U.S. stocks jumped higher Monday on news that trade tensions between China and the U.S. are cooling off. Can stocks continue higher this week? Here are our top stock trades for Tuesday. Top Stock Trades for Tomorrow #1: Celgene (CELG)
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...